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Abstract
Objectives
To systematically review and meta-analyze the current literature in a methodologically rigor-
ous and transparent manner for quantitative evidence on survival outcomes among patients
diagnosed with muscle-invasive bladder cancer that were treated by either trimodal therapy
or radical cystectomy.
Materials and methods
MEDLINE, EMBASE, CENTRAL were systematically searched for comparative observa-
tional studies reporting disease-specific survival and/or overall survival on adult patients
diagnosed with localized muscle-invasive bladder cancer that were exposed to either trimo-
dal therapy or radical cystectomy. Studies qualified for meta-analysis (random effects
model) if they were not at critical risk of bias (RoB).
Results
The literature search identified 12 eligible studies. Three (all rated as “moderate RoB”) out
of 6 studies reporting on disease-specific survival qualified for quantitative analysis and
yielded a pooled hazard ratio (trimodal therapy versus radical cystectomy) of 1.39 (95% con-
fidence interval: 1.03–1.88). Four (mainly rated as “serious RoB”) out of 12 studies were
included in the meta-analysis of overall survival and estimated a hazard ratio of 1.39 (1.20–
1.59).
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Conclusion
Pooled results were significant in favor of radical cystectomy. The conclusion is mainly
driven by large population-based studies that are at high RoB. Hence, the certainty of these
treatment estimates can be considered very low and further research will likely have an
important impact on these estimates. At present, the ultimate decision between trimodal
therapy and radical cystectomy should be left to the patient based on individual preferences
and on the recommendation of a multidisciplinary provider team experienced with both
approaches.
Introduction
Radical cystectomy (RC) is considered the gold-standard therapy for localized muscle-invasive
bladder cancer (MIBC) as demonstrated by large series with long-term follow-up [1, 2]. How-
ever, this procedure is associated with both a substantial decrease in the postoperative quality
of life [3, 4] and also high rates of postoperative morbidity and mortality, estimated to be as
high as 64% and 2.7%, respectively, even in tertiary referral centers [5]. Especially in the sub-
population of high-risk surgical patients and in appropriately selected individuals seeking to
preserve their native bladder, bladder-sparing treatment options have been investigated as an
alternative curative treatment to RC. A trimodal approach consisting of a maximal transure-
thral resection of the bladder tumor (TURBT) followed by radiation therapy (RT) and concur-
rent chemotherapy is currently considered to yield the best oncologic results among bladder-
sparing treatment modalities [6].
While a randomized controlled trial demonstrated superiority of trimodal therapy (TMT)
over bimodal treatment (TURBT followed by RT) for patients with MIBC [7], randomized
controlled evidence comparing TMT and RC is currently neither available nor anticipated [8].
When choosing one of these 2 options, treating physicians and their patients are left with a het-
erogeneous body of evidence consisting of few comparative observational studies. Recently
published systematic reviews and meta-analyses on this research question lack methodological
rigor and transparency with regard to study selection, comprehensive risk of bias assessment
and appropriate quantitative synthesis [9–11]. Further, they yielded discrepant results. In the
absence of a contemporary and internally valid evidence synthesis, we aimed to systematically
review the literature in a methodologically rigorous and transparent manner for quantitative
comparative evidence regarding survival outcomes, namely disease-specific survival and over-
all survival, among adult patients diagnosed with MIBC who were treated either by TMT or
RC.
Materials and methods
Registration, reporting and eligibility criteria
The methods of this systematic review and meta-analysis were specified in advance in a proto-
col and the reporting follows the PRISMA 2009 Checklist (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analysis) [12]. The protocol was prepared in concordance with the
PRISMA-Protocol 2015 Checklist [13] and registered with PROSPERO (International Pro-
spective Register of Systematic Reviews) on February 19, 2018 (registration number:
CRD42018086589; last update: March 1, 2018). Studies: In the absence of randomized con-
trolled trials (RCT) comparing TMT and RC for MIBC regarding survival outcomes, non-
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randomized comparative studies (NRS) were considered as source of evidence as defined in S1
Text.
Population. Studies involving adult patients (>18 years) diagnosed with localized urothe-
lial MIBC were considered regardless of the multiplicity and/or size of the tumor. We excluded
studies involving exclusively non-adult patients (<18 years), locally advanced disease (cT4b
and/or cN1+), systemic disease (M1), non-urothelial histology (predominant), prior trimodal
therapy (as defined later) and/or prior pelvic irradiation regardless of the disease site. Interven-
tion: We defined TMT as maximal TURBT followed by RT and concurrent chemotherapy
regardless of RT dose, type/dose of concurrent chemotherapy, salvage RC regimen, continuous
or split course (see S1 Fig), neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy
(AC). We excluded studies describing: local resection methods other than monopolar/bipolar
TURBT, non-external beam RT, intraarterial chemotherapy, tyrosine-kinase inhibitors, check-
point inhibitors or heterogeneous bladder-sparing arms without reporting of isolated TMT
outcomes.
Comparison. Studies having RC as a comparison arm were considered eligible regardless
of the surgical approach (open/laparoscopic/robot-assisted), type of urinary diversion, extent
of pelvic lymph node dissection (PLND), NAC/AC or neoadjuvant/adjuvant radiation therapy.
Studies exclusively involving simple cystectomy or RC without PLND were not considered
eligible.
Outcomes. Outcomes of interest were disease-specific survival [DSS; defined as time to
death due to bladder cancer] and overall survival [OS; defined as time to death due to any
cause]. Studies were included if they presented a hazard ratio (HR) and/or a Kaplan-Meier
curve.
Timing, setting, language. Neither restrictions to follow-up time, setting nor language
were applied.
Information sources, search, study selection, data collection and data items
MEDLINE (OvidSP), EMBASE (OvidSP) and CENTRAL (Wiley) were searched on February
10, 2018 by a sensitive search strategy (see S1 Table) developed by a health science librarian
with extensive expertise in systematic reviews (EMU). The last search update took place on
August 1, 2018. More information on the development of the search strategy, study selection,
data collection as well as on data items can be found in S1 Text.
Risk of bias assessment
The risk of bias (RoB) was evaluated by the ROBINS-I tool (Risk Of Bias In Non-randomized
Studies–of Interventions) at the outcome level by two independent reviewers (MSW, CJW or
ZK) [14]. Disagreements were resolved by discussion with a third reviewer (MSW, CJW, ZK
or GSK) and audited by the complete team. The evaluation was guided by an iteratively devel-
oped framework that not only incorporates the requirements for a corresponding target trial
but also outlines the most relevant confounding themes based on a causal diagram and defines
warranted adjustment factors (see S2 Fig and S1 Text for more details).
Synthesis of results
The accumulated evidence was first qualitatively synthesized to allow an assessment of the het-
erogeneity of the included studies. The preferred summary measure of the time-to-event out-
comes DSS and OS was the HR. Effect estimates and their corresponding standard errors were
preferably directly abstracted from the studies or mathematically/graphically derived as
described by Tierney et al. [15]. Studies were not eligible for meta-analysis if their overall RoB
Organ preservation versus radical surgery for bladder cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0216255 April 29, 2019 3 / 18
was considered as “critical”. Furthermore, only one population-based study was allowed per
database and per time period to ensure that a single patient does not contribute to the sum-
mary effect more than once. If investigators used different statistical approaches for analysis,
we selected primarily the approach that was least prone to bias and secondarily the most com-
monly used approach in the remaining body of evidence.
Pooling was performed within the strata “single-center studies only” and “all studies”
whereas the latter approach also incorporated population-based studies. The robustness of the
conclusions was further verified by sensitivity analyses in which we iteratively exchanged stud-
ies whose inclusion/exclusion were at high subjectivity. For meta-analyses a random-effects
model according to DerSirmonian & Laird [16] was used as we assumed the true effect size of
TMT versus RC to be heterogeneous across studies. Pooling was performed according to the
generic inverse variance method. Finally, the cumulative evidence was assessed by the GRADE
methodology (Grading of Recommendations Assessment, Development and Evaluation) [17].
All quantitative syntheses were performed in R 3.4.4 (The R Foundation, Vienna, Austria)
using the meta package [18].
Results
Study selection
A total of 12 studies were eligible for inclusion into qualitative synthesis. The PRISMA flow
diagram of the study selection process is presented in Fig 1 and described in more details in S2
Text.
Study characteristics
The characteristics of all eligible studies (N = 12) are presented in Table 1. All studies were of
retrospective nature and recruited patients in the interval between 1995 and 2014 with median
follow-up times ranging from 13 months to 54 months. Five eligible studies were single-center
studies (Israel: 1 [19], Japan: 2 [20, 21], South Korea: 1 [22], Canada: 1 [23]) while 7 studies
were population-based and relied on two partially overlapping United States-based registries
(Surveillance, Epidemiology, and End Results [SEER]-Medicare database: 2 [24, 25], National
Cancer Database [NCDB]: 5 [26–30]) and hence provided a higher number of patients com-
pared to the single-center studies (Nsingle-center: 413, NSEER-Medicare (max): 1843, NNCDB (max):
24169). The majority of the identified studies included cT2-T4/cN0/cM0 patients without any
age restrictions. Ikeda et al. and Kulkarni et al. [20, 23] allowed for cN+ disease. The first study
further focussed on more advanced stages (cT3-T4a) while Bekelman et al. [24] and Smith
et al. [29] limited their cohort to only cT2-T3 and cT2 patients, respectively. Three of the pop-
ulation-based studies applied age restrictions. Fischer-Valuck et al. [26] limited their cohort to
octogenarians while the two SEER-Medicare-based studies [24, 25] allowed only included
patients older or equal to 65/66 years (Bekelman et al./Williams et al.)
All single-center studies described continuous-course TMT regimens including platinum-
based chemotherapy, radiation therapy doses ranging from 49 to 66 Gray (Gy) and various use
of NAC/AC. Two studies [19, 23] further mentioned specific criteria rendering patients TMT-
ineligible. Of the population-based studies, only Ritch et al. and Seisen et al. allowed for captur-
ing of both continuous-course and split-course TMT regimens by way of definition of the
required radiation therapy doses. The remaining population-based studies were restricted by
design to continuous-course regimens and split-course regimens with complete response at re-
evaluation. All population-based studies allowed for various chemotherapy regimens and
information on the use of NAC/AC was not provided. With regards to the RC arms, data on
the extent/utilization of PLND and on the delivery of NAC/AC was sparse although the single-
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center studies provide more information than the population-based ones. The analytic strate-
gies used in the individual studies and the corresponding effect estimates are presented in
Table 2. The effect estimates and standard errors of the 3 studies that used Kaplan-Meier anal-
ysis were derived graphically [19, 21, 26].
Risk of bias assessment
The results of the RoB assessment (overall and stratified by RoB domains) are presented in
Table 3 at the outcome level. One out of 6 studies reporting on DSS was at critical RoB while 2
out of 12 studies reporting on OS were at critical RoB. Details of the comprehensive RoB
assessment are presented in S2 Text, S3 Fig (domain: confounding) and S4 Fig (domain: selec-
tion bias).
Fig 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) flow diagram illustrating the study selection process.
https://doi.org/10.1371/journal.pone.0216255.g001
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Table 1. Study characteristics (N = 12).
Study
Location
Design
Type
Center or
database
Ntotal
Accrual interval
Population Arms (N) including treatment specifications (course, RT dose,
concurrent chemotherapy agents, NAC, AC and extent of
PLND)
Follow-up
(median, months)
Reported
outcomes
Single-center studies
Gofrit, 2015 [19]
Israel
Retrospective
Single center
Jerusalem
N = 66
1998–2008
cT2-T4a
cN0
cM0
TMT arm (33)
• Continuous course
• 62 Gy
• Cisplatin (carboplatin if renal function impaired)
• Exclusion: bulky tumor and/or obstructed kidney
RC arm (33)
• PLND template: common iliac, external iliac, obturator
• NAC or AC: no information available
35 (TMT), 36 (RC) DSS, OS
Ikeda, 2014 [20]
Japan
Retrospective
Single center
Kanagawa
N = 72
2002–2012
cT3-T4a
cN+ (29)
cM0
NUH (4)
TMT arm (40)
• Continuous course
• 55 Gy
• MVAC
• NAC: MVAC (1x)
• AC: MVAC (2x)
RC arm (32)
• PLND template: common iliac, external iliac, internal iliac,
obturator
• AC: no information available
• Exclusion: NAC
20 (TMT), 27 (RC) OS
Kim, 2017 [22]
South Korea
Retrospective
Single center
Seoul
N = 340
2007–2014
cT2-T4
cN0
cM0
TMT arm (32)
• Continuous course
• 60 Gy
• Cisplatin
• 8 patients did not receive concurrent chemotherapy
• NAC (8) or AC (1): gemcitabine-cisplatin x 4
RC arm (308)
• PLND template at surgeon’s discretion
• NAC (26) or AC (6): gemcitabine-cisplatin x 4
31 (TMT), 43 (RC) DSS, OS
Kulkarni, 2017
[23]
Canada
Retrospective
Single center
Toronto
N = 112
2008–2013
cT2-T4
cN+ (20)
cM0
TMT arm (56)
• Continuous course
• 66 Gy
• Cisplatin
• NAC (20): gemcitabine-cisplatin x 4
• Exclusion: tumors > 5cm, multiple tumors, more than mild
hydronephrosis, multifocal carcinoma in situ, impaired bladder
function
RC arm (56)
• PLND template at surgeon’s discretion
• NAC (11) or AC (10): gemcitabine-cisplatin x 4
54 DSS, OS
Nagao, 2017 [21]
Japan
Retrospective
Single center
Ube
N = 84
1994–2011
cT2-T4
cN0
cM0
NUH (8)
TMT arm (42)
• Continuous course
• 49 Gy
• Cisplatin
RC arm (42)
• PLND template: not specified
• NAC/AC: not specified
94 (TMT, mean), 54 (RC,
mean)
DSS, OS
Population-based studies
(Continued)
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Table 1. (Continued)
Study
Location
Design
Type
Center or
database
Ntotal
Accrual interval
Population Arms (N) including treatment specifications (course, RT dose,
concurrent chemotherapy agents, NAC, AC and extent of
PLND)
Follow-up
(median, months)
Reported
outcomes
Bekelman, 2013
[24]
United States
Retrospective
Population-
based
SEER-Medicare
N = 1843
1995–2005
cT2-T3
cN0
cM0
�65 y
TMT arm (417)
• Continuous course or split course with complete response at
re-evaluation
• RT dose not defined
• Platinum-based chemotherapy
• NAC/AC: not specified
RC arm (1426)
• With or without PLND
• No NAC/AC
not reported (end of
observation period: December
2008)
DSS, OS
Cahn, 2017 [30]
United States
Retrospective
Population-
based
NCDB
N = 24169
2004–2013
cT2-T4a
cN0
cM0
TMT arm (1489)
• Continuous course or split course with complete response at
re-evaluation
• 50–80 Gy
• Various single- or multiple agent chemotherapy
• NAC/AC: not specified
RC arm (22680)
• With or without PLND
• NAC/AC: not specified
not reported (end of
recruitment period: December
2013)
OS
Fischer-Valuck,
2018 [26]
United States
Retrospective
Population-
based
NCDB
N = 2279
2004–2013
cT2-T4a
cN0
cM0
80–90 y
TMT arm (958)
• Continuous course or split course with complete response at
re-evaluation
•�50 Gy
• Various single- or multiple agent chemotherapy
• NAC/AC: not specified
RC arm (1231)
• With or without PLND
• No NAC/AC
13 OS
Ritch et al., 2018
[27]
United States
Retrospective
Population-
based
NCDB
N = 3366
2004–2013
cT2-T4
cN0
cM0
NUH
(1244)
TMT arm (1686)
• Continuous or split course
•�40 Gy
• Various single- or multiple agent chemotherapy
• NAC or AC: not specified
RC arm (1686)
• With or without PLND
• NAC/AC: not specified
45 OS
Seisen et al.,
2017 [28]
United States
Retrospective
Population-
based
NCDB
N = 12843
2004–2011
cT2-T4
cN0
cM0
TMT arm (1257)
• Continuous or split course
• 60–65 Gy (or�39 Gy if followed by immediate salvage RC)
• Various single- or multiple agent chemotherapy
• NAC/AC: not specified
RC arm (11586)
• With or without PLND
• NAC/AC: not specified
44 OS
Smith et al., 2014
[29]
United States
Retrospective
Population-
based
NCDB
N = 13428
1998–2010
cT2
cN0
cM0
TMT arm (3724)
• Not specified
RC arm (9704)
• With or without PLND
• NAC/AC: not specified
33 (TMT), 38 (RC) OS
(Continued)
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Disease-specific survival
The effect estimates and 95%-CIs of the identified studies that report on DSS (N = 6) are visu-
ally presented in the Forest plot of Fig 2A. The results of the single-center studies are all incon-
clusive with effect estimates in favor of TMT. Among the two population-based studies,
Bekelman et al. reported one analytic strategy based on instrumental variable analysis (IVA)
with a non-significant result (HR in favor of RC) and 3 non-IVA analytic strategies that were
all significant or borderline significant (effect estimates in favor of RC). The recently published
study of Williams et al. was the only identified investigation that reported on DSS and demon-
strated clearly significant results in favor of RC (HR: 1.55 [95%-CI: 1.32–1.83]).
With regard to pooling of the single-center studies we a priori excluded the investigations
of Gofrit et al. and Nagao et al. due to “critical RoB” and due to potentially unreliable graphical
effect size derivation in the presence of only a few outcome events, respectively. As both popu-
lation-based studies relied on the same database and have a prominent overlap of 4 years, we
selected Williams et al. for inclusion into the meta-analysis since this study in comparison to
Bekelman et al. provided a more recent cohort and also used a comparable analytic strategy as
Kim et al. and Kulkarni et al. Moreover, Bekelman et al. limited their study to cT2-T3 patients
and all of their strategies except the IVA approach, which relies on strong assumptions, were at
serious RoB. Fig 2B presents the pooled analysis within the strata “single-center studies only”
(N = 2) and “all studies” (N = 3). The first analysis led to a non-significant summary measure
of 0.94 (0.51–1.72), while the second one demonstrated a significant result in favor of RC (1.39
[1.03–1.88]). The latter result, however, did not statistically withstand sensitivity analyses in
which the SEER-Medicare-based study of Williams et al. was iteratively replaced by the two
analytic strategies of Bekelman et al. (IVA and propensity score-adjusted regression analysis,
see S5 Fig).
Overall survival
Twelve studies reported on OS and their effect sizes and 95%-CIs are presented in Fig 3A
(stratified by single-center studies and population-based studies). As for DSS, all single-center
Table 1. (Continued)
Study
Location
Design
Type
Center or
database
Ntotal
Accrual interval
Population Arms (N) including treatment specifications (course, RT dose,
concurrent chemotherapy agents, NAC, AC and extent of
PLND)
Follow-up
(median, months)
Reported
outcomes
Williams et al.,
2018 [25]
United States
Retrospective
Population-
based
SEER-Medicare
N = 1374
2002–2011
cT2-T4a
cN0
cM0
�66 y
TMT arm (687)
• Continuous course or split course with complete response at
re-evaluation
• 60 to 66 Gy
• Chemotherapy containing cisplatin or fluorouracil
+ mitomycin C
• NAC/AC: not specified
RC arm (687)
• With or without PLND
• NAC (99)
• AC: not specified
not reported (claims data
available until December 2013)
DSS, OS
AC, adjuvant chemotherapy; DSS, disease-specific survival; Gy, Gray; IPTW, inverse probability treatment weighting; N, number of patients; NAC, neoadjuvant
chemotherapy; NCDB, National Cancer Database; NUH, non-urothelial histology; OS, overall survival; PLND, pelvic lymph node dissection; RC, radical cystectomy;
RT, radiation therapy; SEER, Surveillance, Epidemiology, and End Results; TMT, trimodal therapy.
https://doi.org/10.1371/journal.pone.0216255.t001
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studies (N = 5) provide inconclusive effect estimates with 95%-CIs that included the HR of 1.
While all provided HRs in favor of TMT, the study of Ikeda et al., which was restricted to
cT3-cT4 patients, reported effect estimates in favor of RC. Population-based studies relying on
SEER-Medicare (Bekelman et al. and Williams et al.) demonstrated comparable patterns on
the Forest plot as for DSS (see Fig 2A). The 5 population-based investigations from the NCDB
displayed heterogeneity. Cahn et al., Ritch et al. and Seisen et al. who included cT2-T4 N0 M0
Table 2. Analytic strategies used in individual studies and the corresponding effect estimates (hazard ratioTMT versus RC).
Study
Location
NTMT NRC Analysis DSS
[HR (95% CI)]
OS
[HR (95% CI)]
Single-center studies
Gofrit, 2015
Israel
33 33 Hard matching followed by Kaplan-Meier analysis 0.81 (0.31–
2.12)�
0.95 (0.38–
2.37)�
Ikeda, 2014
Japan
40 32 1. Multivariable regression analysis 1.63 (0.72–
3.69)
2. Propensity score-adjusted regression analysis 1.55 (0.69–
3.49)
Kim, 2017
South Korea
32 308 1. Multivariable regression analysis 0.87 (0.39–
2.03)
29 50 2. Propensity score matching followed by adjusted regression analysis 0.96 (0.38–
2.47)
0.89 (0.47–
2.03)
Kulkarni, 2017
Canada
56 56 Propensity score matching followed by adjusted regression analysis (DSS: accounting for
competing risks)
0.92 (0.41–
2.04)
0.85 (0.43–
1.66)
Nagao, 2017
Japan
42 42 Propensity score matching followed by Kaplan-Meier analysis 0.61 (0.27–
1.36)�
0.54 (0.26–
1.11)�
Population-based studies
Bekelman, 2013
United States
417 1426 1. Multivariable regression analysis 1.28 (0.98–
1.68)
1.26 (1.07–
1.50)
2. Propensity score-adjusted regression analysis 1.31 (0.97–
1.77)
1.26 (1.05–
1.53)
3. Inverse probability weighting-adjusted regression analysis 1.34 (1.02–
1.77)
1.27 (1.06–
1.53)
4. Instrumental variable analysis 0.94 (0.55–
1.18)
1.06 (0.78–
1.31)
Cahn, 2017
United States
1489 22680 1. Multivariable regression analysis 1.58 (1.47–
1.69)
14891 14891 2. Hard and propensity score matching followed by unadjusted regression analysis 1.40 (1.24–
1.60)
Fischer-Valuck,
2018
United States
958 1231 1. Multivariable regression analysis 0.92 (0.83–
1.01)
650 650 2. Propensity score matching followed by Kaplan-Meier analysis 0.99 (0.88–
1.13)�
Ritch, 2018
United States
1686 1686 Propensity score matching followed by adjusted regression analysis 1.5 (1.2–1.8)
Seisen, 2017
United States
1257 11586 Inverse probability weighting-adjusted regression analysis 1.37 (1.16–
1.59)
Smith, 2014
United States
3724 9704 Multivariable regression analysis 1.05 (0.98–
1.12)
Williams, 2018
United States
687 687 Propensity score matching followed by unadjusted regression analysis (DSS: accounting for
competing risks)
1.55 (1.32–
1.83)
1.49 (1.31–
1.69)
CI, confidence interval; DSS, disease-specific survival; HR, hazard ratio; N, number of patients; OS, overall survival; RC, radical cystectomy; TMT, trimodal therapy.
�Graphical derivation.
1assumed.
https://doi.org/10.1371/journal.pone.0216255.t002
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patients without any age restrictions estimated treatment effects significantly in favor of RC.
Fischer-Valuck et al. and Smith et al. who focused on octogenarians and cT2 tumors, respec-
tively, both reported non-significant treatment effects close to an HR of 1 with narrow 95%-
CIs.
Only the study of Kulkarni et al. was rated as “moderate RoB” with regard to the outcome
OS. Due to earlier described reasons we excluded the investigations of Gofrit et al. and Nagao
et al. from the pooling of single-center studies reporting on OS. Furthermore, we decided to
withdraw Ikeda et al. because of the exclusion of cT2 patients. The incorporation of popula-
tion-based studies was limited to one SEER-Medicare-based investigation and one NCDB
study, respectively. With regard to SEER-Medicare studies we preferred Williams et al. to
Bekelman et al. as outlined earlier while we decided for the NCDB investigation of Seisen et al.
The latter decision was based on the critical risk of bias assessment of Cahn et al., the age
restrictions of Fischer-Valuck et al., the focus on cT2 tumors of Smith et al. and on the fact that
Seisen et al. in comparison to Ritch et al. not only performed a sensitivity analysis for immortal
time bias but also excluded non-urothelial histology.
Table 3. Risk of bias assessment at the outcome level.
Study Outcome Domains Overall
Confounding Selection of
participants
Classification of
intervention
Deviations from
intended
intervention
Missing
data
Measurement of
outcomes
Selection of the
reported results
Single-center studies
Gofrit, 2015 DSS critical low low low low low moderate critical
OS critical low low low low low moderate critical
Ikeda, 2014 OS serious Ø information low low low low moderate serious
Kim, 2017 DSS moderate moderate low low low low moderate moderate
OS serious moderate low low low low moderate serious
Kulkarni,
2017
DSS moderate low low low low low moderate moderate
OS moderate low low low low low moderate moderate
Nagao, 2017 DSS moderate Ø information low low low low moderate moderate
OS serious Ø information low low low low moderate serious
Population-based studies
Bekelman,
20131
DSS serious moderate low low low low moderate serious
OS serious moderate low low low low moderate serious
Bekelman,
20132
DSS moderate moderate low low low low moderate moderate
OS moderate moderate low low low low moderate moderate
Cahn, 2017 OS critical moderate low low low low moderate critical
Fischer-
Valuck, 2018
OS serious moderate low low low low moderate serious
Ritch, 2018 OS serious moderate low low low low moderate serious
Seisen, 2017 OS serious moderate low low low low moderate serious
Smith, 2014 OS serious moderate low low moderate low moderate serious
Williams,
2018
DSS moderate moderate low low low low moderate moderate
OS serious moderate low low low low moderate serious
low, Low RoB in this domain/overall; moderate, Moderate RoB in this domain/overall; serious, Serious RoB in this domain/overall; critical, Critical RoB in this domain/
overall; Ø information, No information on which to base a judgement about RoB for this domain/overall.
DSS, disease-specific survival; OS, overall survival; RoB, risk of bias.
1Multivariable regression analysis, propensity score-adjusted regression analysis or inverse probability weighting-adjusted regression analysis.
2Instrumental variable analysis.
https://doi.org/10.1371/journal.pone.0216255.t003
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The result of this meta-analysis is presented in Fig 3B. Pooling among single-center studies
showed an inconclusive effect in favor of TMT (0.87 [0.51–1.46]) while the addition of the two
selected population-based studies yielded an estimate statistically significantly in favor of RC
(1.39 [1.20–1.59]). We performed several sensitivity analyses for the latter result in which we
exchanged the study of Seisen et al. by the investigation of Ritch et al. and/or the work of Wil-
liams et al. by the study of Bekelman et al. (IVA approach and propensity score-adjusted
regression analysis). All sensitivity analyses except the ones incorporating the IVA approach of
Bekelman et al. were statistically robust (see S6 Fig).
Fig 2. Individual study results of studies reporting on disease-specific survival (A, N = 6) and the corresponding meta-analysis (B, N = 3). The
numbers in brackets next to the study names correspond to the numbers in Table 2 and represent different analytic strategies. CIs in this figure might
differ to the reported CIs in Table 2 at the 2nd decimal place due to imprecisions associated with log transformations. CI: confidence interval; HR:
hazard ratio; RC: radical cystectomy; TMT: trimodal therapy.
https://doi.org/10.1371/journal.pone.0216255.g002
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Fig 3. Individual study results of studies reporting on overall survival (A, N = 12) and the corresponding meta-analysis (B, N = 4). The
numbers in brackets next to the study names correspond to the numbers in Table 2 and represent different analytic strategies. CIs in this figure
might differ to the reported CIs in Table 2 at the 2nd decimal place due to imprecisions associated with log transformations. CI: confidence interval;
HR: hazard ratio; RC: radical cystectomy; TMT: trimodal therapy.
https://doi.org/10.1371/journal.pone.0216255.g003
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Discussion
This study systematically synthesized comparative evidence on DSS and OS for patients diag-
nosed with MIBC who were treated either by TMT or RC. Three out of 6 eligible studies that
report on DSS were considered “moderate RoB” and qualified for quantitative analysis that
demonstrated a result in favor of RC (1.39 [1.03–1.88]). Among 12 eligible studies providing
effect estimates with regard to OS, 4 investigations could be included into a meta-analysis ren-
dering a pooled estimate clearly in favor of RC (1.39 [1.20–1.59]). However, 3 out of the 4 stud-
ies incorporated into this quantitative synthesis were rated as “serious RoB”. Studies focusing
on cT2 tumors or on older patients with higher competing risks demonstrated inconclusive
results on OS. For both outcomes DSS and OS, we detected comparable patterns in the body
of evidence which consisted on one hand of small-sample single-center studies with wide 95%-
CIs and HRs close to 1 or slightly in favor of TMT and on the other hand of United States-
based research at the population level with narrow 95%-CIs and effect estimates that were pre-
ponderantly in favor of RC.
There are several explanations for the heterogeneity in results between single-center studies
and population-based studies. First, TMT is a complex treatment modality that requires a
highly specialized and multidisciplinary provider team to select ideal patients, perform a maxi-
mal TURBT, safely apply chemoradiation, perform cystoscopic follow-up examinations in
bladders heavily altered by postradiation changes and to rigorously recommend and perform
salvage RC in the event of treatment failure. While the single-center studies provide evidence
from such specialized provider teams (efficacy), the population-based studies rather report
more generalizable, population-wide and real-world estimates (effectiveness). It is generally
known that efficacy results are more in favor of an intervention (i.e. in this case, TMT) than
effectiveness results. Second, platinum-based concurrent chemotherapy as well as salvage RC
are integral components of true TMT. Therefore, the circumstance that the NCBD studies
could not determine the receipt of platinum-based therapy and the obviously different salvage
RC rates between single-center studies and population-based studies (11% in Kulkarni et al.
[23] versus 2% in Ritch et al. [27]) might also partially explain the heterogeneity.
Third, the exposure (TMT versus RC)–outcome (DSS, OS) relationship is moderately
(DSS) and strongly (OS) confounded by the comorbidity/performance of the patient and even
sophisticated analytic strategies as utilized in certain studies cannot exclude unmeasured con-
founding. Reliable measurement of relevant confounding domains is thus crucial to address
confounding bias as much as possible. All population-based studies used the Charlson Comor-
bidity Index to address the confounding theme “comorbidity/performance”. Bekelman et al.
[24] performed in addition an IVA which theoretically accounts for both measured and
unmeasured confounding [31]. Although such a methodology relies on strong theoretical
assumptions, they could demonstrate a change of the effect estimate in the direction of the null
hypothesis. Hence, a larger amount of unmeasured confounding in the population-based stud-
ies because of a lack of performance status measures could be another explanation for the het-
erogeneity in results between single-center studies and population-based studies.
The strengths of our approach are as follows: First, we performed a comprehensive and rig-
orous RoB assessment using the ROBINS-I instrument. Prior published systematic reviews
and meta-analyses on the same research question either used the Newcastle-Ottawa Scale
(NOS) [11] / Methodological Index for Non-Randomized Studies (MINORS) [10] for RoB
assessment or did not perform a RoB assessment [9]. We strongly believe that a detailed RoB
assessment in this setting is not only highly warranted but also that the ROBINS-I instrument
is by design superior to the NOS/MINORS tools when it comes to the evaluation of confound-
ing bias, the most important bias influencing our research question. Second, our meta-analysis
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involved, according to best practice, pooling of sufficiently adjusted HRs. Prior meta-analyses
either pooled unadjusted HRs of comparative studies [11], quantitatively synthesized studies
that are at diametral different RoB [10] or simply compared pooled survival estimates of sepa-
rate TMT series and RC series with a t-test [9], all of which are severely biased strategies to
draw causal inference for the current research question due to confounding, heterogeneity and
ecological bias, respectively. Third, in the presence of experimental evidence favoring concur-
rent chemotherapy during RT to RT alone [7] we only included TMT arms in which a majority
of patients received concurrent chemotherapy; prior systematic reviews and meta-analyses
included a mix of bimodal and trimodal therapy [9–11]. Fourth and finally, this work repre-
sents updated systematic summary of comparative evidence of TMT versus RC for MIBC (last
search update: August 1, 2018). Such an updated search was highly warranted as 8 out of 12
identified studies were published in 2017 or 2018 and prior evidence syntheses utilized out-
dated searches from 2013 [9] and 2016 [11].
However, this evidence synthesis is not without limitations. First, the overall quality of evi-
dence is limited by the observational nature of the included studies. Therefore, this investiga-
tion is still biased by unmeasured confounding and cannot provide better quality of evidence
than “moderate RoB” and “serious RoB” for DSS and OS, respectively, Second, all population-
based studies originated from two United States-based databases and suffer not only from par-
tial overlap between the databases but also from significant overlap within each database.
Thus, we were only able to include two population-based studies from two different databases
into quantitative synthesis. Since the decisions to include/exclude such studies were prone to
some subjectivity, we tried to attenuate this by using as explicit and objective selection criteria
as possible and by performing sensitivity analyses. Unfortunately, most of the sensitivity analy-
ses were highly influential as each population-based study included a high number of patients.
Third, thorough RoB assessment is driven by the quality and quantity of the provided study
information. The latter was often a limiting factor in the absence of pre-registered protocols.
However, we tried to mitigate this limitation by contacting study authors if relevant details
were lacking. Fourth and finally, several studies were designed and conducted according to
our eligibility criteria but, unfortunately, analyzed and presented in an inefficient way that
does not allow for drawing causal inference.
The findings of this systematic review and meta-analysis are summarized in the format of
the GRADE evidence profile (see S2 Table). Based on this methodology, the certainty of evi-
dence for both outcomes DSS and OS was rated as “very low” due to the RoB and the inconsis-
tency of results. Thus, based on the available evidence at this time, the choice between TMT or
RC for MIBC depends on individual patient preferences, the recommendation of a multidisci-
plinary provider team experienced with both approaches and consideration of immediate sur-
gical mortality associated with RC versus hypothetically worse oncological long-term
outcomes related to TMT.
We highly expect that further research will have an important impact on the confidence in
the estimate of the treatment effect. As we do not expect landmark results from experimental
research within the near future [8], the arrival of further observational comparative research
has to be awaited. As a lesson learned from this systematic review and meta-analysis, such
investigations have to fulfil certain requirements such as rigorous adjustment for confounding
bias (including the incorporation of comorbidity indexes and performance measures), mean-
ingful subgroup analyses (such as by age and clinical T stage), full methodological and analyti-
cal transparency (including use of online appendices in light of strict word count limitations),
strict adherence to reporting guidelines (STROBE Statement (Strengthening the Reporting of
Observational Studies in Epidemiology) [32]) and, if population-based, incorporation of non-
United States jurisdictions.
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Conclusions
TMT is an alternative to RC for MIBC, especially in patients with a high operative risk and in
those not willing to sacrifice their bladder. This study systematically synthesized the currently
available observational comparative evidence both qualitatively and quantitatively. Pooled
results were significant in favor of RC (DSS: moderate RoB, OS: serious RoB). However, the
favorability of RC is mainly driven by the large population-based studies that are at high risk
for confounding or information bias. Therefore, the certainty of these treatment estimates can
be considered very low and further research will likely have an important impact on these esti-
mates. As no randomized evidence that would ultimately state superiority/non-inferiority of
one of the two modalities in a confounding-free setting is expected in the near future, high-
quality comparative studies thoroughly adjusting for tumor characteristics and comorbidities/
performance are warranted to guide clinical decision-making in the meantime.
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